Why Is TREVI THERAPEUTICS I (TRVI) Stock Down Today?

Trevi Therapeutics Inc (TRVI) fell 12.06% to $16.77 in morning trading. The stock's sharp decline came despite recent analyst upgrades and price target increases. The move suggests a broader market reassessment or a reaction to underlying fundamentals that have not yet aligned with the positive analyst sentiment.

What Happened

BMO and H.C. Wainwright both issued positive analyst ratings for TRVI in the past 36 hours. BMO initiated coverage with an Outperform rating and a $36 price target. H.C. Wainwright raised its price target to $24. B. Riley Securities also maintained a Buy rating and raised its price target to $31. These developments indicate growing confidence in the company's prospects. However, the stock's significant drop implies that investors may be taking a more cautious stance, possibly due to profit-taking or a reassessment of risk in the biotech sector. The stock has not yet shown a corresponding rally in response to the analyst activity.

What The Data Shows

Trevi Therapeutics has a market capitalization of $2.7 billion and remains unprofitable with a trailing twelve-month earnings per share of -0.32. The stock has a beta of 1.00, meaning it moves in line with the broader market. Over the past 52 weeks, TRVI has traded between $6.55 and $20.22. The current price of $16.77 is within this range but shows a notable pullback from its recent highs. The stock's volatility and unprofitable status may contribute to its sensitivity to broader market shifts and analyst-driven optimism.

What To Watch

Trevi Therapeutics has no upcoming earnings report scheduled. Investors will want to monitor the breadth of analyst coverage and any further price target adjustments from key firms.